US Bioservices is now dispensing DUPIXENT

March 30, 2017

The U.S. Food and Drug Administration recently approved Sanofi and Regeneron’s DUPIXENT (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.